

Radiotherapy Bed Model Multi-Objective Pareto-Interior Dual-Optimization for Prostate Cancer Hyper Fractionated Treatment Planning

Francisco Casesnoves*

PHD Engineering, MSC Physics-Mathematics, Physician, Independent research scientist, International Association of Advanced Materials, Sweden, Uniscience Global Scientific Member, Wyoming, USA

***Corresponding author:** Francisco Casesnoves, PHD Engineering, MSC Physics-Mathematics, Physician, Independent research scientist, International Association of Advanced Materials, Sweden, Uniscience Global Scientific Member, Wyoming, USA

ARTICLE INFO

Received: 📅 March 23, 2025

Published: 📅 April 10, 2025

Citation: Francisco Casesnoves. Radiotherapy Bed Model Multi-Objective Pareto-Interior Dual-Optimization for Prostate Cancer Hyper Fractionated Treatment Planning. Biomed J Sci & Tech Res 61(2)-2025. BJSTR.MS.ID.009584.

ABSTRACT

In a previous publication, constrained evolutionary algorithms for *In-Vitro*-BED-LQ model (Linear Quadratic Biological Effective Dose Model) in prostate cancer Hyperfractionation radiotherapy TPO were optimized with Pareto-Multiobjective (PMO) methods. This study improves the research with a further comparative *In-Vitro*-BED-LQ model optimization followed by a precision-refinement with Interior Optimization (IO) methods. Complex software is developed based on hyper fractionation constraints, but within vivo main parameters dataset, and IO programming. Results with software design algorithmic method take in handle subroutines functions and matrix-algebra method for setting constraints and 3D IO surfaces. Results with 3D Interior Optimization by using the Genetic Algorithms (GA) previous numbers show get very good precision with new-invention of isodoselines sharp determination. Solutions dataset is shortly compared with previous in vitro study. Findings prove comparative PMO 2D imaging charts and numerical values of PMO prostate cancer hyper fractionated TPO parameters. Applications for prostate tumors radiotherapy planning, especially with new Surfactal- Isodoselines, brain prostate metastases and stereotactic radiosurgery treatments are briefed.

Keywords: Pareto-Multiobjective Optimization (PMO); Mathematical Methods (MM); Biological Models (BM); Radiation Therapy (RT); Initial Tumor Clonogenes Number Population (NO); Effective Tumor Population Clonogenes Number (NEffective); Linear Quadratic Model (LQM); Integral Equation (IE); Tumor Control Probability (TCP); Normal Tissue Complications Probability (NTCP); Biological Effective model (BED); Tumor Control Cumulative Probability (TCCP); Radiation Photon-Dose (RPD); Nonlinear Optimization, Interior Optimization (IO); Radiotherapy Treatment Planning Optimization (TPO); Nonlinear Optimization; Treatment Planning Optimization (TPO); Artificial Intelligence (AI); Pareto-Multiobjective Optimization (PMO); Genetic Algorithms (GA)

Introduction and Objectives

From a previous publication, [1], the objective of this contribution is apply Constrained Genetic Algorithms and 3D Interior Optimization on radiotherapy BED-LQ model for prostate tumors [2-33] with *in vivo* dataset for an hyperfractionated schedule. The BED-LQ model [2-40], is useful for low dose fractions, while LQL and PTL ones are more appropriate for high dose delivery RT treatment schedules—namely, hypofractionated treatment [33]. The numerical difference between *in vitro* LQ parameters for prostate LQ model can be considered important [1-45]. It is not subject of this article any discussion about hyperfractionation versus hypofractionation dose delivery.

Prostate cancer epidemiology statistics-figures are within the group of highest incidences- prevalence cancers, but lower than lung and breast tumors, [45]. Therefore, the objective of the study is to carry out a double optimization process. Firstly, 2D GA optimization with *in vivo* data for LQ model. Secondly, making the most of the firstly GA obtained results, to get an improved refinement by using 3D Interior Optimization methods. Numerically, TPot magnitude difference *in vivo* values, prostate cancer, are about 28 days *in vivo* and [3,20] *in vitro* ones are lower. In general, also, both *in vitro* and *in vivo* TPot parameters for prostate tumors are greater than other types of cancer [21-25,46].

This fact implies a longer survival time with several proper characteristics related to different treatment stages. Namely, surgical, RT, radiosurgical, chemotherapy, immunotherapy, hormonal therapy, combinations of all of them. Today, biomarkers are getting an important role in order to predict the survival time, optimal chemotherapy, and both characteristics at the same time [41]. Table 1 shows a biomarkers classification into P-Biomarkers (Biomarkers for Prognosis, [42]), T-Biomarkers (Biomarkers for Optimal Treatment), and H-Biomarkers (Hybrid Biomarkers Group), [Author’s proposal]. The programming design has two parts: Nonlinear GA-PMO engineering software with matrix algebra constraints, similar to the previous publication in codes/patterns for PMO-BED models. Second part is rather more difficult. That is, 3D Interior Optimization with the new useful-practical

finding of isodoselines for radiotherapy planning hyper fractionated schedule. Those new Isodoselines along the Interior Optimization surface constitute a TPO advance and innovation of this contribution. Results comprise Graphical and Numerical TPO hyper fractionated RT treatment planning. 2D GA graphics are presented in several formats, for 100, 150, and 250 generations. 3D Interior Optimization charts are illustrated with Isodoselines, optimal areas, and numerical data inset. Numerical results show first GA figures and Interior Optimization refined values. Therefore, the novelty of this article, based on the previous evolutionary optimization paper, [1], is its GA algorithms and computational optimization with *in vivo* parameters, 3D Interior Optimization improvements, and the practical definition of 3D Isodoselines for RT planning hyperfractionated schedule.

Table 1: General Biomarkers classification, [Author’s proposal]. Nano-Biomarkers is an open research field with potential perspectives in future [42,45]. Just remark that Biomarkers are is extant, diverse and difficult as involves biochemistry, molecular biology, medicine-pharmacology, medical physiology and several other fields. Therefore, this Table is simple based on Author’s proposal classification.

Biomarkers general classification for cancer radiotherapy treatment [author’s proposal]			
Type	Application	Additional	Examples
P-BIOMARKER (PROGNOSIS BIOMARKER)	Prediction of approximate survival time subject to optimal treatment	Prediction for approximate survival based on specific tumor cell histology, and according to the relation histology-efficacy of drugs. Drug failure investigation utility.	Research clinical trial example, [from 42]: investigation data show that patient survival time in PD-L1- positive patients who are treated with combined anti-CTLA-4 and anti-PD-1 is not superior to nivolumab monotherapy. That implied that was necessary further research. This clinical-trial study area is difficult
T-BIOMARKER (TREATMENT BIOMARKER)	Selection of approximate optimal choice for effective chemo-immuno drug-target treatment	Optimization of the best effective drug type for personalized tumor at every patient. Detection of optimal drug-target and pharmacokinetics. Drug failure patient-personalization investigation. Target characterization.	HSP90a is an inducible molecular chaperone that functions as a homodimer [ref 42, Chapter 2.4, Table 2.4.2]
H-BIOMARKER (HYBRID BIOMARKER)	Both prediction of survival time and optimal treatment	Those ones that can make both functions, or one of them better than the other	Nano-Biomarkers actually in investigation can modify the immuno- cells and efficacy of drugs over cells tumor

It is objective, according to the precision of numbers obtained, that the mathematical and software developed is considered appropriate. Grosso modo, a double constrained optimization based on previous Nonlinear Pareto-Multiobjective GA optimization was developed with the addition of 3D Interior Optimization refinement and the new- practical Isodoselines definition. Applications for radiotherapy hyperfractionated BED-TPO planning are presented. Numerical Analysis precision results are gonna be promising for improvements of the method.

Mathematical and Computational Methods

Following previous studies, mainly the prostate cancer one [1],

and publications for Breast, Head- Neck cancer, here the Pareto-Multiobjective Optimization Fowler-foundation BED Effective model was programmed, [1-40,45,47]. Alpha, Betha, and rest of parameters intervals are detailed in Table 2. Algorithms 1-5 set the 2D GA and 3D IO formulas and constraints [26-27,48-49]. Radiobiological parameters Alpha and Betha are implemented independently, not in quotient [alpha/beta] because of the programming pattern’s purpose. This low-dose LQ-BED model constitutes the foundations for hyper fractionated radiotherapy TPO, though there are dissimilarities among authors [21-25,46]. Therefore, the Pareto-Multiobjective [Algorithm 1] that was set, with Chebyshev L1 norm, [Algorithms 2-4] is presented firstly. The IO method is explained secondly.

Table 2: Software implemented dataset for GA programming with source references [1,42,43, 62,63-65].

In vivo LQ model parameters Implemented	
[Chapman, Nahum, 2015, Joiner, Kogel, 2019]	
LQ Model Parameters Implemented [From author’s refs [23,24,97]]	
Bed-Parameter	Magnitude/Interval
T_{Pot}	[26.00, 30.00] (Days)
T_K	21 (Days)
$T_{Treatment}$	[30, 40] (Days)
Number of Fractions	[37, 45] (Fractions)
Fraction Dose interval	[1.00, 2.00] Gy
Pareto Total Prostate Dose Objective Function [89]	Pareto 1 :70 Gy Pareto 2 :78 Gy

Evolutionary Algorithms Mathematical Method

The GA algorithms used are approximately the same than in previous prostate cancer publication, [1]. The sequence of the formula’s development is as follows,

Minimize

$$F(\vec{X}) = (f_1(\vec{X}), f_2(\vec{X}), \dots, f_N(\vec{X})),$$

subject to,

$$K_i(\vec{X}) \geq 0, \text{ for } i = 1, \dots, M$$

(Algorithm 1)

Where

F(x): Main function to be optimized.

fi (x): Every function of same variables (x).

Ki (x): Constraints functions such as in general $N \neq M$.

BED nonlinear-quadratic model has been adapted for *in vivo* parameter TPot magnitude. Then, PMO in Prostate, [1,25,27,28] tumors simplest BED model reads,

Chebyshev L_1 Optimization,

for $i=1, 2, \dots$ minimize pareto,

DOSE, - BED_{Effective} | L_1 With,

$$BED_{Effective} = k \times d \times \left[1 + \frac{d \times \beta}{\alpha} \right] - \dots$$

$$\dots - \frac{Ln(2)}{\alpha} \times \left[\frac{T_{Treatment} - T_{Delay}}{T_{Potential}} \right]$$

(Algorithm 2)

where,

BED: The basic algorithm for Biological Effective Dose initially developed by Fowler et Al. [1,23-25, 28-33,46].

k: Optimal Number of fractions for hyperfractionated TPO. Optimization parameter. [1,23-25,28-33,46]. d: Optimal Dose magnitude for every fraction. Optimization Parameter [Gy]. [23-25,28-33,46].

α : The basic algorithm constant for Biological Effective Dose models. Radiobiological experimental parameter *in vivo*. [Gy-1]. [23-25,28-33,46].

β : The basic algorithm constant for Biological Effective Dose models *in vivo*. Radiobiological experimental parameter. [Gy-2]. Note that it is very usual to set in biological models [α / β in Gy].

TTreatment: The overall TPO time. This parameter varies according to authors’ and institutions/hospitals criteria. [1,23-25,28-33,46].

TDelay: The overall TPO time delay for clonogens re-activation. This parameter varies according to authors’ experimental research.

TPotential: The potential time delay for tumor cell duplication. This parameter varies according to authors’ experimental-theoretical research.

DOSE: The dose magnitudes for lung cancer simulation algorithm for Biological Effective Dose [1,23-25, 28-33,46]. Software patterns were calculated around intervals prostate DOSE ϵ [35-39,50-53] Gy.

Algorithm 1 [Fowler mainly, modified by Casesnoves, 98]. Prostate PMO algorithm [2-29,46,48,49] implemented in software. Table 2 shows these intervals for optimization parameters details. Programming was developed in Matlab® system. At programming trials, it was found that precision was increased related to *in vitro* parameters [1]. The constraints algebraic algorithm developed for Pareto-Multi-objective problem, [Algorithms-3-5, Casesnoves 2023] reads,

Constraints,

For Pareto Functions $i = 1, 2,$

and lower – upper lim its of

optimization parameters,

$$S_{Lower} \leq K_i + d_i + T_{(Treatment)i} \leq S_{Upper}$$

(Algorithm 3)

Where,

SLOWER: Summatory of all lower constraints for parameters [K, d, T]. SUPPER: Summatory of all upper constraints for parameters [K, d, T]. Ki: Dose fraction number parameter for [i = 1, 2].

di: Dose fraction magnitude parameter for [i = 1, 2]. TTREATMENT: Treatment time magnitude parameter for [i = 1, 2].

The subroutines programming strategy, as in [98], which are implemented reads,

Matrix A lgebra Subroutines
For Constraint S,

$$[A1] \times \begin{pmatrix} K \\ d \\ T \end{pmatrix} \leq \begin{pmatrix} S_{K_{max}} \\ d_{d_{max}} \\ T_{T_{max}} \end{pmatrix},$$

$$[A2] \times \begin{pmatrix} K \\ d \\ T \end{pmatrix} \geq \begin{pmatrix} S_{K_{max}} \\ d_{d_{max}} \\ T_{T_{max}} \end{pmatrix},$$

(Algorithm 4)

where,

SK,d,T : Upper (maximum) and Lower boundaries for parameters [K, d, T], according to Algorithms 1- 2.

A1,2: Matrices for numerical values, Table 2.

Software used for this study continues previous algorithms papers [1,2-21,25,27,28,35,47] with modifications, and addition of IO programs. For GA-PMO modeling, Equation 1 and Algorithms 1-4 are implemented on 2D programs, with application of Algorithm 5 basic model formula. Algorithm 2 was programmed with Algorithm 3 matrix constraints subroutines-functions. Table 2 shows Constrained GA Optimization *in vivo* parameters, different from [1], implemented in Algorithms 1-5. From Table 3 results, after IO implementation, 3D IO dataset for Table 4 is got. From all these numbers, 3D IO and 2D Genetic Algorithms Graphical Optimization imaging-processing charts, error determinations, pareto-distance, get precise approximations for hyper fractionated PMO-BED model. In general, precision obtained is more than expected, Tables 3 & 4.

Table 3: Constrained optimization Algorithms 1-4 numerical results. Pareto distance is almost exact, in contrast with previous *in vitro* research (in [1], was about 10-2 magnitude order).

Genetic algorithm optimization numerical results for prostate tumors <i>in vivo</i> parameters hyper fractionated rt treatment		
PARAMETER [Optimization with [refs [25,83]] and related author's radiotherapy text books] criteria]	MAGNITUDE INTERVAL/EXACT NUMERICAL GA RESULT	ADDITIONAL
Optimal Dose fraction number	[40] Fractions	Usual protocol in literature [2- 22,35-40,43,55, ,61,97,98]
Optimal Dose fraction magnitude	[1.7319] Gy	Usual protocol in literature [2- 22,35-40,43,55, ,61,97,98]. Set with intervals according to different criteria.
T _{Treatment}	[38] Days	Usual protocol in literature [2- 22,35-40,43,55, ,61,97,98]. Set with intervals according to different criteria. The RT treatment varies according to weekends breaks, secondary effects, patient circumstances, etc.
Dose interval in Objective Function That was set at software patterns	70 Gy for Pareto F function 1 78 Gy for Pareto F function 2	Usual protocol in literature [2- 22,35-40,43,55, ,61,97,98]. Set with two total dose Pareto Functions according to different criteria.
Pareto Distance	0 Almost exact	Usual protocol in literature [2- 22,35-40,43,55, ,61,97,98]. Set with two total dose Pareto Functions according to different criteria.
Average Distance	0 Almost exact	Usual protocol in literature [2- 22,35-40,43,55, ,61,97,98]. Set with two total dose Pareto Functions according to different criteria.

Table 4: Brief of IO constrained optimization Algorithms 1-4 numerical results, with description of two Isodoselines, Figure 7. From Table 2, Lower Isodoseline is for 70 Gy, Upper for 78 Gy. K figures are truncated to integers.

Interior optimization numerical results for prostate tumors in vivo parameters hyperfractionated rt Treatment [dataset from Figure 7]		
FRACTIONS NUMBER K [Trunkated]	FRACTION DOSE d Gy	TOTAL DOSE Gy
37	2.00	ISODOSELINE 78 Gy
38	1.44	ISODOSELINE 78 Gy
39	1.04	ISODOSELINE 78 Gy
36	1.95	ISODOSELINE 70 Gy
38	1.14	ISODOSELINE 70 Gy

Interior Optimization Computational Method

3D Interior and Graphical Optimization methods are used to confirm and refine the *in vivo* precision of the GA results from [1]. This is an advance as it was found that by using Interior Optimization the precision is increased and Isodoselines can be set for TPO. The method and software developed is a potential new application for accurate TPO.

Programming Dataset

Table 2 shows Matlab Constrained GA optimization dataset is detailed, for first optimization stage. As in [98], constraints matrix algebra is implemented through [Algorithms 3-5]. All these simulation

techniques come from [1,21-33,35,36,46-49,54,55]. The *in vivo* TPotential in prostate cancer for setting data is TPotential ϵ [56-60] days. The reason to use *in vivo* dataset in this second prostate study is that, although currently the *in vivo* radiobiological differences differ in the literature, more realistic results are gonna get.

2D Evolutionary Algorithms Optimization Results

2D GA Graphical results are shown in Figures 1-4. The constrained optimization results are presented sharply in 2D multifunctional charts. This constrained optimization with *in vivo* parameters, [Algorithms 1-5] gets better results than *in vitro* one in the previous prostate cancer study [1].




Figure 1: High precision, almost null average distance, reached with 100 generations constrained optimization Multifunctional GA 2D graph. Note the total accomplishment of both pareto functions. The upper chart is the most important graph given by software when PMO is performed to validate the GA-optimization precision. In this study all programmed optimizations show null residuals, therefore, results are better than [1].




Figure 2: Stepping up to 150 generations, image shows triple-graph for GA constrained optimization. The first one is the most important graph given by software when PMO is performed to validate the GA-optimization precision. Average distance among individuals is almost null, exact fitness. The fundamentals of Nonlinear PMO calculations are usually based on 2D PMO functions charts.




Figure 3: 200 generations constrained optimization Multifunctional GA 2D graph. Score Histogram shows the accuracy. The upper-left image is the most important graph given by software when PMO is performed to validate the GA-optimization precision. 100% of criteria is met.




Figure 4: 250 generations constrained optimization Multifunctional GA 2D graph. Score Histogram shows the accuracy. The upper-left image is the most important graph given by software when PMO is performed to validate the GA-optimization precision. 100% of criteria is met.

3D Interior Optimization Results

The imaging process software shows the results got with 3D Interior

Optimization, Figures 5-7. Results are very acceptable. Isodose-lines are marked inset every image. The radiotherapy planner gets multiple choices by using this 3D IO method.




Figure 5: The fundamentals of IO calculations are implemented into a 3D surface. Pattern intervals for plotting were taken from PMO Table 3 figures. Note that about 80 Gy BED total dose is fixed along Isodose-line, while (k) and (d) parameters vary when cursor is moved along this Isodose-line.




Figure 6: Area for BED doses lower/equal than 70 Gy is marker in yellow inset. That is under the Isodoseline. Pattern intervals for plotting were taken from PMO Table 3 figures. Note that about 70 Gy BED total dose is fixed along Isodoseline, while (k) and (d) parameters vary when cursor is moved along this Isodoseline.




Figure 7: The Isodoselines fundamentals for IO calculations are implemented into a 3D surface with two examples. Namely, about 70 and 78 Gy. Pattern intervals for plotting were taken from PMO Table 3 figures. Note that each BED total dose is fixed along Isodoseline, while (k) and (d) parameters vary when cursor is moved along this Isodoseline. Intermediate values are marked in-between the Isodoseline for 78 Gy.

Invention of Interior Optimization Isodoselines

When performing the 3D Interior Optimization refinement, it was found that Isodoselines can be feasible and useful. Figure 7 can be considered a definite demonstration. It shows a number of selected Isodoselines for a number of TPO-dose magnitudes to prove the new utility found. For IO, the algorithm to be set on program patterns reads,

$$BED_{Effective} = k \times d \times \left[1 + \frac{d \times \beta}{\alpha} \right] - \dots$$

$$\dots - \frac{Ln(2)}{\alpha} \times \left[\frac{T_{Treatment} - T_{Delay}}{T_{Potential}} \right];$$

Algorithm (5)

where all the parameters description are at Algorithms 1-4.

An image processing showing the utility for PTO of this IO with several Isodoselines is presented, Figure 7. Note that Algorithm 5 is converted when running software in a nonlinear-quadratic system of equations. As it is quadratic, the rationale of the precise results is justified.

Numerical Results

Numerical results can be divided into two parts. First one is the GA numerical figures, Table 3. Secondly IO results brief based on Figure 7 mainly. In Figure 7 Isodoselines demonstrate their efficacy for TPO choice. That is, once fixed total dose, e.g., 70 or 78 Gy, any planner can select the desired number of fractions, and the convenient figure of fraction-dose along a Isodoseline, Figure 7 proof.

Genetic Algorithm Optimization Numerical Results

Figures for constrained PMO-GA optimization numerical data are presented shown in Table 3. As occurred in [98], constrained optimization displays acceptable numbers within numerical intervals [1,2-40,47].

Interior Optimization Optimization Numerical Results

Table 4 show the accurate numerical results got with IO refinement method. Example-dataset included comes from Isodoselines of Figure 7.

Radiotherapy Treatment Planning Applications

Table 5 presents details and applications of both optimization techniques. Radiotherapy hyperfractionated treatment planning applications for prostate tumors are specified. Medical Physics principal applications for radiotherapy research emerge from the data.

Table 5: Details for radiotherapy and radioprotection for RT prostate cancer TPO Medical Physics study applications. Derived from these results, dual-optimization (GA+IO) can be considered acceptable.

Bed-LQ radiotherapy optimization applications for hyper fractionated rt protocol With <i>in vivo</i> parameters		
[ga + 3d interior optimization]		
Application	Medical, Physics And Radiation Oncology Field	Interior Optimization and Additional
Optimal number of fractions	RT schedule	All variety of selection within Isodoselines/ Avoid side effects (Figure 7)
Optimal fraction dose	RT schedule	All variety of selection within Isodoselines/ Avoid side effects (Figure 7)
Change/chose the total dose with Isodoselines At 3D IO surface	RT schedule	All variety of selection within Isodoselines/ Avoid side effects (Figure 7)
Biological Models TCP TCCP Improvements	Patient Treatment Precision	Radioprotection improvements, more Quality Life and OARS Radioprotection
Post-RT Treatment Survival time	Decrease of TCP, and TCCP	Increase of Survival Time
Biological Models Research	Improvements	Improvements LINAC Software, Cyberknife®, Gammaknife® And Imaging guided TR Treatment
NTCP Models	Possible applications also	Decrease of Side-Effects at OARS

Discussion and Conclusions

The objective of the study was to apply firstly constrained 2D GA Optimization for prostate cancer hyper fractionated RT treatment with BED-LQ model and *in vivo* parameters. Secondly to get precise numbers by using 3D Interior Optimization methods. Constrained PMO-Multiobjective method was programmed with subroutines. A rather difficult software for 3D Interior Optimization to determine optimal surfaces and Isodoselines was designed. In general, for first stage, the previous publication algorithms were set. First part of results comprises a group of 2D GA plots and numerical dataset. Constrained Optimization with Algorithms 1-5 got to get a Pareto Distance almost exact, null, with 250 generations. Interior Optimization application in second stages resulted in the invention of Isodoselines along the optimal surface, also with accuracy, Figure 7. These Isodoselines give a large number of alternatives in terms of number of fractions and magnitude of fractions keeping the same total BED dose.

It is considered a practical invention for RT planning with BED models. When number of generations increases from 100, the running time of the constrained programs rises to approximately 1-3 minutes. As a rule, numerical and graphical results are better than expected. One of the reasons because of which GA-*in vivo* parameters method gonna get such precision, is the parameter magnitude of TPot *in vivo*. The second part of BED equation becomes lower and the model results almost be a quadratic nonlinear equation with k and d variables. As a result, the GA Optimization is simpler for computation and reaches more computational precision. The method can be considered somehow laborious but the precision gained results are justified. Inconvenient is the increase of running time when using GA in direct proportion to the increment of generations number. The software to construct precise 3D Interior Surfaces and Isodoses has to be checked and done carefully. Grosso modo, a prostate cancer constrained RT-BED hyper fractionation model with GA and *in vivo* data was performed with Pareto-Optimization and refined with 3D Interior Optimization. Isodoselines constitute a practical result for BED RT accurate planning. Applications for prostate tumors and radiation therapy in general optimal TPO emerge from all the study.

Scientific Ethic Standards

Formulas applied/included are from previous prostate article with *in vitro* data. Model is a modification from several authors, based also on [21,25,27,28,46,61] techniques. Mathematical Algorithms 1-4 formulas are modified from previous publications [21,25,27,28,46,61]. RT applications methods for these publications were created by Dr Casesnoves in 2021-2. Methods from [21,26,27] were created by Dr Francisco Casesnoves in 3rd November 2016, and Interior Optimization Methods in 2019. BED model setting in Algorithms and programming were developed by Dr Casesnoves from previously published BED models. This article has previous papers information, from [2-22], whose inclusion is essential to make the

contribution understandable. This study was carried out, and their contents are done according to the International Scientific Community and European Union Technology and Science Ethics [62-65]. References [62-65]: 'European Textbook on Ethics in Research'. European Commission, Directorate-General for Research. Unit L3. Governance and Ethics. European Research Area. Science and Society. EUR 24452 EN. And based on 'The European Code of Conduct for Research Integrity'.

Revised Edition. ALLEA. 2017. This research was completely done by the author; the computational-software, calculations, images, mathematical propositions and statements, reference citations, and text is original for the author. When a mathematical statement, algorithm, proposition or theorem is presented, demonstration is always included. When a formula is presented, all parameters are detailed or referred. If any results inconsistency is found after publication, it is clarified in subsequent contributions [Note: in at least one article of these series, it was written by mistake that radiation is previous to surger. That is a mistake, for cancer treatment, surgery, when possible, is previous to radiation]. When a citation such as [Casesnoves, 'year'] is set, it is exclusively to clarify intellectual property at current times, without intention to brag. The article is exclusively scientific, without any commercial, institutional, academic, religious, religious-similar, non-scientific theories, personal opinions, political ideas, or economical influences. When anything is taken from a source, it is adequately recognized. Ideas and some text expressions/sentences from previous publications were emphasized due to a clarification aim [62-98].

References

1. Casesnoves F (2023) Radiotherapy BED Model 2D Pareto- Multiobjective Evolutionary Optimization for Prostate Cancer Hyperfractionated Treatment. Biomed J Sci & Tech Res 51(2).
2. Casesnoves F (2022) Radiotherapy Wedge Filter AAA Model 18 Mev-Dose Delivery 3D Simulations with Several Software Systems for Medical Physics Applications. Applications Biomed J Sci & Tech Res 40(5): 32222-32235.
3. Casesnoves F (2016) Mathematical Exact 3D Integral Equation Determination for Radiotherapy Wedge Filter Convolution Factor with Algorithms and Numerical Simulations. Journal of Numerical Analysis and Applied Mathematics 1(2): 39-59.
4. Casesnoves F (2015) Radiotherapy Conformal Wedge Computational Simulations, Optimization Algorithms, and Exact Limit Angle Approach. International Journal of Scientific Research in Science, Engineering and Technology (IJSRSET) 1(2): 353-362.
5. Casesnoves F (2019) Improvements in Simulations for Radiotherapy Wedge Filter dose and AAA-Convolution Factor Algorithms. International Journal of Scientific Research in Science, Engineering and Technology (IJSRSET) 6(4): 194-219.
6. Casesnoves F (2011) Exact/Approximated Geometrical Determinations of IMRT Photon Pencil-Beam Path Through Alloy Static Wedges in Radiotherapy Using Anisotropic Analytic Algorithm (AAA). Peer-reviewed ASME Conference Paper. ASME 2011 International Mechanical Eng Congress. Denver. USA, pp. 851-862.

7. Casesnoves F (2012) Geometrical Determinations of Limit angle (LA) related to maximum Pencil-Beam Divergence Angle in Radiotherapy Wedges. Peer-reviewed ASME Conference Paper: ASME 2012 International Mechanical Eng Congress. Houston. USA. IMECE2012- 86638.
8. Casesnoves F (2013) A Conformal Radiotherapy Wedge Filter Design. Computational and Mathematical Model/Simulation'. Peer-Reviewed Poster IEEE (Institute for Electrical and Electronics Engineers), Northeast Bioengineering Conference. Syracuse New York, USA. April 6th, 2013. Peer-Reviewed Poster Session on 6th April 2013. Sessions 1 and 3 with Poster Number 35. Page 15 of Conference Booklet Printed.
9. Casesnoves F (2014) Mathematical and Geometrical Formulation/Analysis for Beam Limit Divergence Angle in Radiotherapy Wedges. Peer-Reviewed International Engineering Article. International Journal of Engineering and Innovative Technology (IJEIT) 3(7): 232-243.
10. Casesnoves F (2014) Geometrical determinations of IMRT photon pencil-beam path in radiotherapy wedges and limit divergence angle with the Anisotropic Analytic Algorithm (AAA) Casesnoves, F. Peer- Reviewed scientific paper, both Print and online. International Journal of Cancer Therapy and Oncology 2(3): 02031.
11. Casesnoves F (2014) Radiotherapy Conformal Wedge Computational Simulations and Nonlinear Optimization Algorithms. Peer-reviewed Article, Special Double-Blind Peer- reviewed paper by International Scientific Board with contributed talk. Official Proceedings of Bio- and Medical Informatics and Cybernetics: BMIC 2014 in the context of the 18th Multi-conference on Systemics, Cybernetics and Informatics: WMSCI 2014 July 15 - 18, 2014, Orlando, Florida, USA. ISBN: 978-1-941763-03-2 (Collection).
12. Casesnoves F (2007) Large-Scale Matlab Optimization Toolbox (MOT) Computing Methods in Radiotherapy Inverse Treatment Planning'. High Performance Computing Meeting. Nottingham University. Conference Poster.
13. Casesnoves F (2008) A Computational Radiotherapy Optimization Method for Inverse Planning with Static Wedges. High Performance Computing Conference. Nottingham University. Conference Poster.
14. Casesnoves F (2015) Radiotherapy Conformal Wedge Computational Simulations, Optimization Algorithms, and Exact Limit Angle Approach. International Journal of Scientific Research in Science, Engineering and Technology 1(2): 353-362.
15. Casesnoves F (2015) Radiotherapy Standard/Conformal Wedge IMRT-Beamlet Divergence Angle Limit Exact Method, Mathematical Formulation, and Bioengineering Applications. International Article-Poster. Published in Proceedings of Conference. 41st Annual Northeast Bioengineering Conference. Rensselaer Polytechnic Institute USA 17-19.
16. Casesnoves F (2015) Radiotherapy Standard/Conformal Wedge IMRT-Beamlet Divergence Angle Limit Exact Method, Mathematical Formulation, and Bioengineering Applications. IEEE (Institute for Electrical and Electronics Engineers), International Article-Poster.
17. Casesnoves F (2015) Abstract-Journal. 'Radiotherapy Standard/ Conformal Wedge IMRT- Beamlet Divergence Angle Limit Exact Method, Mathematical Formulation. International Conference on Significant Advances in Biomedical Engineering. 252nd OMICS International Conference 5(1).
18. Casesnoves, F (2001) Determination of absorbed doses in common radio diagnostic explorations. 5th National Meeting of Medical Physics. Madrid, Spain. September 1985. treatment Planning'.
19. Casesnoves, F (2001). Master Thesis in Medical Physics. Eastern Finland University. Radiotherapy Department of Kuopio University Hospital and Radiotherapy Physics Grouversity-Kuopio. Defense approved in 2001. Library of Eastern finland University. Finland.
20. Casesnoves F (2013) A Conformal Radiotherapy Wedge Filter Design. Computational and Mathematical Model/Simulation'. Peer-Reviewed Poster IEEE (Institute for Electrical and Electronics Engineers), Northeast Bioengineering Conference. Syracuse New York, USA. Presented in the Peer-Reviewed Poster Session on 6th April 2013. Sessions 1 and 3 with Poster Number 35. Page 15 of Conference Booklet. April 6th, 2013.
21. Casesnoves F (2022) Radiotherapy Biological Tumor Control Probability Integral Equation Model with Analytic Determination. International Journal of Mathematics and Computer Research 10(8): 2840-2846.
22. Casesnoves F (2022) Radiotherapy Wedge Filter AAA Model 3D Simulations For 18 Mev 5 cm-Depth Dose with Medical Physics Applications". International Journal of Scientific Research in Computer Science, Engineering and Information Technology (IJSRCSEIT) 8(1): 261-274.
23. Walsh S (2011) Radiobiological modelling in Radiation Oncology. PhD Thesis. School of Physics. National University of Galway.
24. Chapman D, Nahum, A (2015) Radiotherapy Treatment Planning, Linear-Quadratic Radiobiology. CRC Press.
25. Mayles, W, Nahum A, Rosenwald J (2015) Handbook of Radiotherapy Physics. (2nd Edn.), CRC Press. International Standard Book Number-13: 978-1-4987-2146-2.
26. Casesnoves F (2023) Radiotherapy Genetic Algorithm Pareto-Multiobjective Optimization of Biological Effective Dose and Clonogens Models for Head and Neck Tumor Advanced Treatment. International Journal of Mathematics and Computer Research 11(1): 3156-3177.
27. Casesnoves F (2023) Radiotherapy effective clonogens model graphical optimization approaching linear quadratic method for head and neck tumors. International Journal of Molecular Biology and Biochemistry 5(1): 33-40.
28. Casesnoves F (2023) Training course Stereotactic Radiotherapy and Radiosurgery in Management of Metastatic Brain Tumors. Sigulda Stereotactic, Radiosurgery and Cyber knife Hospital. International Society of Radiosurgery. Sigulda, Latvia.
29. Joiner M, Kogel A (2019) Basic Clinical Radiobiology.
30. Cher M, Honn Kenneth V, Raz A (2002) Prostate Cancer: New Horizons in Research and Treatment. Kluwer Academic Publishers.
31. Sureka C, Armpilia C (2017) Radiation Biology for Medical Physicists. CRC Press.
32. Ramon J, Denis L (2007) Prostate Cancer. Springer-Verlag Berlin Heidelberg.
33. B. Andisheh B, M Edgren, Dž Belkić, P Mavroidis, A Brahme, et al. (2013) A Comparative Analysis of Radiobiological Models for Cell Surviving Fractions at High Doses. Technology in Cancer Research and Treatment 12(2): 183-192.
34. Tamames Escobar S (2000) Cirugia/ Surgery: Aparato Digestivo. Aparato Circulatorio. Aparato Respiratorio/ Digestive System. Circulatory System. Respiratory System (Spanish Edn.,).
35. Casesnoves F (2018) Practical Radiotherapy TPO course and practice with Cyberknife. Robotic simulations for breathing movements during radiotherapy treatment. Sigulda Radiotherapy Cyberknife Center. Latvia. Riga National Health Oncology Hospital Varian LINACs TPO practice/lessons several Varian LINACs. Riga Technical University Bioengineering Training-Course Nonlinear Life.
36. Casesnoves F (2022) Radiotherapy Linear Quadratic Bio Model 3D Wedge Filter Dose Simulations for AAA Photon-Model [18 Mev, Z= 5,15 cm] with Mathematical Method System. Biomed J Sci & Tech Res 46(2)-2022.

37. Casesnoves F (1985) Master in Philosophy Thesis at Medical Physics Department. Protection of the Patient in Routinary Radiological Explorations. Experimental Low Energies RX Dosimetry. Medicine Faculty. Madrid Complutense University.
38. Casesnoves F (1983-5) Ionization Chamber Low Energies Experimental Measurements for M-640 General Electric RX Tube with Radcheck ionization camera, Radcheck Beam Kilovoltmeter and TLD dosimeters. Radiology Department practice and measurements. Madrid Central Defense Hospital. Medical Physics Department. Master in Philosophy Thesis. Medicine Faculty. Complutense University. Madrid.
39. Casesnoves F (1985) Determination of Absorbed Doses in Routinary Radiological Explorations. Medical Physics Conference organized by Medical Physics Society Proceedings Printed. San Lorenzo del Escorial. Madrid.
40. Greening J (1985) Fundamentals of Radiation Dosimetry. (2nd Edn.), Taylor and Francis.
41. Casesnoves F (2018) Training work. Nonlinear Life Biomedical Training-Course. Riga Technical University and Riga Oncology Hospital.
42. Carini H, Fidock M, Van Gooland A (2019) Handbook of Biomarkers and Precision Medicine. CRC Press.
43. Joiner M, Kogel A (2019) Basic Clinical Radiobiology. CRC Press.
44. Chen A, Vijayakumar S (2011) Prostate Cancer. Radiation Medicine Rounds. Demos Medical 2(1).
45. Nahum A, Webb S (1993) A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. *Physics in Medicine and Biology* 38(6): 653-666.
46. Luenberger D (1989) Linear and Nonlinear Programming (2nd Edn.), Addison-Wesley.
47. Casesnoves F (2022) Radiotherapy 3D Isodose Simulations for Wedge Filter 18 Mev-Dose [$z = 5,15$ cm] with AAA Model with Breast Cancer Applications. *International Journal on Research Methodologies in Physics and Chemistry (IJRPC)* 9(2).
48. Garden A, Beadle B, Gunn G (2018) Radiotherapy for Head and Neck Cancers. Fifth Edition. Wolters Kluwer.
49. Ragaz, J, Ivo A Olivotto, John J Spinelli, Norman Phillips, Stewart M Jackson, et al. (2005) Regional Radiation Therapy in Patients with High-risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the Columbia Randomized Trial'. *Journal of National Cancer Institute* 97(2): 116-126.
50. Steuer R (1986) Multiple Criteria Optimization: Theory, Computation and Application. Wiley.
51. Spirou SV, Chui CS (1998) A gradient inverse planning algorithm with dose-volume constraints. *Med Phys* 25(3): 321-323.
52. Das I, colls (1997) Patterns of dose variability in radiation prescription of breast cancer. *Radiotherapy and Oncology* 44(1): 83-89.
53. (1977) International Commission of Radiation Protection. Bulletin 26th. The International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. Pergamon Press. Copyright © 1977 The International Commission on Radiological Protection.
54. Stanton P, T G Cooke, G Forster, D Smith, J J Going (1996) Cell kinetics *in vivo* of human breast cancer. *British Journal of Surgery* 83(1): 98-102.
55. Haydaroglu, A, Ozyigit G (2013) Principles and Practice of Modern Radiotherapy Techniques in Breast Cancer. Springer.
56. Casesnoves F (2019-20) Die numerische Reuleaux-Methode Rechnerische und dynamische Grundlagen mit Anwendungen (Erster Teil).
57. Ulmer W, Harder D (1997) Corrected Tables of the Area Integral $I(z)$ for the Triple Gaussian Pencil Beam Model. *Z Med Phys* 7: 192-193.
58. Ulmer W, Harder D (1995) A triple Gaussian pencil beam model for photon beam treatment planning. *Med Phys* 5: 25-30.
59. Ulmer W, Harder D (1996) Applications of a triple Gaussian pencil beam model for photon beam treatment planning. *Med Phys* 6: 68-74.
60. Fowler J (2010) 21 years of Biologically Effective Dose. *The British Journal of Radiology* 83 (991): 554-568.
61. (2013) Ethics for Researchers. EU Commission. Directorate-General for Research and Innovation. Science in society/Capacities FP7.
62. (2021) European Commission, Directorate-General for Research. Unit L3. Governance and Ethics. European Research Area. Science and Society.
63. ALLEA (2017) The European Code of Conduct for Research Integrity, Revised Edn., ALLEA: Berlin Barndenburg Academy of Sciences.
64. (2017) Good Research Practice. Swedish Research Council.
65. Ma C, Lomax T (2013) Proton and Carbon Ion Therapy. CRC Press.
66. Censor Y, Zenios S (1997) Parallel Optimization: Theory, Algorithms and Applications. UOP.
67. Ulmer W, Pyryr J, Kaissl W (2005) A 3D photon superposition/ convolution algorithm and its foundation on results of Monte Carlo calculations. *Phys Med Biol* 50(8): 1767-1790.
68. Ulmer W, Harder D (1997) Applications of the triple Gaussian Photon Pencil Beam Model to irregular Fields, dynamical Collimators and circular Fields. *Phys Med Biol*.
69. Haddad K, Anjak O, Yousef B (2019) Neutron and high energy photon fluence estimation in CLINAC using gold activation foils. *Reports of practical oncology and radiotherapy* 24(1): 41-46.
70. Sievinen J, Waldemar U, Kaissl W. AAA Photon Dose Calculation Model in Eclipse™. Varian Medical Systems Report. Rad #7170A.
71. Vagena E, Stoulos S, Manolopoulou M (2016) GEANT4 Simulations on Medical LINAC operation at 18MV: experimental validation based on activation foils. *Radiation Physics and Chemistry* 120: 89-97.
72. Casesnoves F (1981) Surgical Pathology I course class notes and clinical practice of Surgical Pathology Madrid Clinical Hospital [Professor Surgeon Dr Santiago Tamames Escobar]. 4th academic year course for graduation in Medicine and Surgery. Lessons and practice Breast Cancer Surgical and Medical Treatment. 1980-1981. Madrid Complutense University.
73. Formenti S, Sandra Demaria S (2013) Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift Silvia C. Formenti, Sandra Demaria. *J Natl Cancer Inst* 105: 256-265.
74. Numrich R, (2010) The computational energy spectrum of a program as it executes. *Journal of Supercomputing* 52: 119-134.
75. Ulmer W, Schaffner B (2011) Foundation of an analytical proton beamlet model for inclusion in a general proton dose calculation system. *Radiation Physics and Chemistry* 80: 378-389.
76. Sharma S (2008) Beam Modification Devices in Radiotherapy. Lecture at Radiotherapy Department, PGIMER. India.
77. Barrett A, Colls (2009) Practical Radiotherapy Planning. (4th Edn.), Hodder Arnold.

78. Ahnesjö A, Saxner M, A Trepp (1992) A pencil beam model for photon dose calculations. *Med Phys* 19(2): 263-273.
79. Brahime A (2000) Development of Radiation Therapy Optimization. *Acta Oncologica* 39(5): 579-595.
80. Bortfeld T, Hong T, Craft D, Carlsson F (2008) Multicriteria Optimization in Intensity- Modulated Radiation Therapy Treatment Planning for Locally Advanced Cancer of the Pancreatic Head. *International Journal of Radiation Oncology and Biology Physics* 72(4): 1208-1214
81. Brown B, cols (2014) Clinician-led improvement in cancer care (CLICC) - testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial - study protocol. *Implementation Science* 9: 64.
82. Bortfeld T (2006) IMRT: a review and preview. *Phys Med Biol* 51(13): R363-R379.
83. Censor Y (1996) Mathematical Optimization for the Inverse problem of Intensity-Modulated Radiation Therapy. Laboratory Report Department of Mathematics University of Haifa Israel.
84. Capizzello A, Tsekeris PG, Pakos EE, Papatathanasopoulou V, Pitouli EJ (2006) Adjuvant Chemo-Radiotherapy in Patients with Gastric Cancer. *Indian Journal of Cancer* 43(4): 174-179.
85. Tamer Dawod, EM Abdelrazek, Mostafa Elnaggar, Rehab Omar (2014) Dose Validation of Physical Wedged symmetric Fields in Artiste Linear Accelerator. *International Journal of Medical Physics Clinical Engineering and Radiation Oncology* 3: 201-209.
86. Do SY, David A, Bush Jerry D Slater (2010) Comorbidity-Adjusted Survival in Early-Stage Lung Cancer Patients Treated with Hypofractionated Proton Therapy. *Journal of Oncology* 2010: 251208.
87. Ehrgott M, Burjony M. (1999) Radiation Therapy Planning by Multicriteria Optimization. Department of Engineering Science University of Auckland New Zealand Conference Paper.
88. Ezzel G (1996) Genetic and geometric optimization of three-dimensional radiation therapy treatment planning. *Med Phys* 23(3): 293-305.
89. (2008) Effective Health Care. Number 13. Comparative Effectiveness of Therapies for Clinically Localized Prostate cancer.
90. Hansen P (1998) Rank-deficient and discrete ill-posed problems: numerical aspects of linear inversion. SIAM monographs on mathematical modelling and computation.
91. Hashemiparast S, Fallahgoul H (2011) Modified Gauss quadrature for ill-posed integral transform. *International Journal of Mathematics and Computation* 13(11).
92. Isa N (2014) Evidence based radiation oncology with existing technology. *Reports of practical oncology and radiotherapy* 19(4): 259-266.
93. Johansson KA, Mattsson S, Brahme A, Turesson I (2003) Radiation Therapy Dose Delivery. *Acta Oncologica* 42(2): 85-91.
94. Khanna P, Blais N, Gaudreau PO, Corrales Rodriguez L (2016) Immunotherapy Comes of Age in Lung Cancer. *Clinical Lung Cancer* 18(1): 13-22.
95. Kufer KH, Hamacher HW, Bortfeld T (2000) A multicriteria optimisation approach for inverse radiotherapy planning. University of Kaiserslautern Germany.
96. Kirsch A (1996) An introduction to the Mathematical Theory of Inverse Problems. Springer Applied Mathematical Sciences.
97. Hedman M, Bjork Eriksson T, Brodin O, Toma Dasu I (2013) Predictive value of modelled tumour control probability based on individual measurements of *in vitro* radiosensitivity and potential doubling time. *Br J Radiol* 86(1025): 20130015.
98. Marcu L, al (2018) Radiotherapy and Clinical Radiobiology of Head and Neck Cancer. Series in Medical Physics and Biomedical Engineering. CRC Press.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2025.61.009584

Francisco Casesnoves. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>

Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>